• Bionaturis and ADL Biopharma will create a European biotechnological benchmark.
• The integration operation is subject to the pertinent approvals.
• After the integration, a capital increase is planned to enhance the free-float, the liquidity of the shares and to finance the growth of the integrated company
• Black Toro Capital, the fully owners of ADL Biopharma, will control 85% of the resulting company.
Bionaturis (ticker BNT) have just signed a binding integration agreement with ADL Biopharma, a company specialized in industrial bioprocessing of fermentation-based products with applications in human and animal health.This integration agreement aims to build-up a European leader in red biotechnology, focused mainly on the development and commercialization of high-value fermentation-based bioproducts.

Bionaturis will add its capacity to develop premium products and its position as a reference partner of the One Health concept, and ADL will contribute with one of the biggest fermentation sites in Europe and with a broad customer portfolio. The integration will produce many synergies for both companies, highlighting the level of complementarity of their customers and products. The resulting company will offer a broader spectrum of products and services, covering different features and needs of the steady growing human and animal health sectors.
Pilar de la Huerta, CEO of ADL Biopharma, has stated: “Bionaturis innovation capacity along with the industrial capacity of ADL will expand quickly our products and market opportunities, enhancing our growth significantly, and positioning the integrated company as a leader in Southern Europe in the development and production of fermentation bioproducts for human and animal applications”.
For Victor Infante, CEO of Bionaturis Group, as a reference partner in the One Health concept the operation “will increase our customer base, expand the industrial production capacity of our premium products and will enhance our innovation in the fields of human and animal health. The new structure will help us optimize the value capture of our good positioning in the steady growing animal health sector”
For Ramon Betolaza, Managing Partner of Black Toro Capital, “the combination of Bionaturis and ADL Biopharma, highly complementary, crystallizes the value of our investment in ADL Biopharma, as well as creates a reference in red biotechnology in the Spanish Stock Exchange for SMEs”
The execution of this binding agreement is subject to the preceptive market, legal and shareholders approvals and the resulting integrated company will keep trading on the Spanish Stock Exchange for SMEs. The integration will lead to a change of the current shareholder structure. ADL‘s shareholder (BTC) will hold 85 percent of the entity resulting from integration meanwhile the current shareholders of Bionaturis would hold 15 percent.
About Bionaturis
As a reference partner in the One Health concept, Bionaturis Group offers premium biotechnological products and services for human and animal health. It consists of four companies (Bionaturis, Biobide, ZIP Solutions and BNT Pacific) and two subsidiaries (Biobide USA and BNT China Biosciences) spread across Europe, Asia and the US. Bionaturis is listed on the stock exchange with the ticker BNT. Through a B2B business model, the animal health division of Bionaturis has developed premium products, both prescription and non-prescription products, for production animals (FPAs) and pets (CAPs).
About ADL Biopharma
ADL Biopharma is one of the European references for the development and production of projects by fermentation processes, with a total capacity of 2,400 cubic meters, the largest fermentation facility in southern Europe. ADL Biopharma carries out its activity in three differentiated and complementary business lines: manufacture of active pharmaceutical ingredients (API’s); development and scaling-up services for third parties (CRO); and industrial production by contract through fermentation processes (CMO). The company employs over 250 people and its markets are located mainly in Europe and the United States.